Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
Kelly Chibale describes the drug discovery process as a fairy-tale quest, stating, 'It doesn't mean that there aren't surprises or miracles. They do happen, but you have to kiss many frogs before you meet the prince.' This metaphor illustrates the challenges and unpredictability in finding effective medicines.
On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.
Public health consultant Dr Ross Keat said supporting people earlier to make small preventative changes would make "a big difference later on". Some 3,500 people in the north of the island within that age bracket are eligible for the checks. The checks will be carried out by two pre-existing nurses that support GP staff and would not replace GP appointments, Keat explained, adding that the cost would be minimal and absorbed by Ramsey Group Practice.
If it continues to spread past the demarcation that we usually draw using a skin marker-we say Sharpie, but it's a skin marker-we say that this is spreading. Diagnosis: possible sepsis. Varshavski was not talking to the patient or to nursing staff. He was not even in a hospital. He was speaking into a camera in a two-bedroom apartment on the fifty-sixth floor of a building in Hell's Kitchen, in a makeshift studio where he records videos and his popular podcast.
Martschenko's argument is largely that genetic research and data have almost always been used thus far as a justification to further entrench extant social inequalities. But we know the solutions to many of the injustices in our world-trying to lift people out of poverty, for example-and we certainly don't need more genetic research to implement them. Trejo's point is largely that more information is generally better than less.
As the Magerstadt Professor of Cardiovascular Epidemiology, Khan studies the epidemiology of risk for heart failure. Using population-based cohorts and large electronic health record data analyses, she performs mechanistic studies that may enhance risk prediction and identify novel therapeutic agents for the prevention and treatment of cardiovascular disease. Khan and her team have developed a tool to predict risk and prevent cardiovascular disease such as heart failure, stroke, arrhythmia, coronary artery disease and many other conditions.
Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.
Between March 2020 and March 2022, over 100 million telemedicine services were delivered to approximately 17 million Australians. The Australian government invested $409 million to make telehealth permanent, whilst the UK announced £600 million for digital health infrastructure in April 2025. Patient adoption is equally impressive: 60% find telemedicine more convenient than in-person appointments, 55% report higher satisfaction with teleconsultations, and 74% of millennials prefer virtual appointments for routine care. These aren't temporary shifts; they represent a fundamental transformation in healthcare delivery.
AI plays an important role-but not by fixing fragmented data on its own. The work of organizing, connecting, and interpreting healthcare information still belongs to people and the systems they build. Where AI helps is after that foundation is in place: by bringing the right information forward at the right time, reducing the effort it takes to find what matters, and supporting better decisions in the moment of care.